What's in the pipeline for the treatment of Parkinson's disease?


Journal Article (Review)

Parkinson's disease (PD) is a common, debilitating neurodegenerative disorder that creates a significant burden for patients, family members and society at large. Major unmet needs include effective therapies that could favorably modify the underlying pathogenetic processes in PD, and better control of motor and nonmotor symptoms in advanced-stage disease. This review examines the current state of development of potential PD therapies, including dopaminergic therapies, modulators of adenosine and glutamate receptors, cell-based therapies, genetic therapies and device-based therapies. In addition, research into potential neuroprotective agents and pipeline therapies for nonmotor symptoms of PD are summarized.

Full Text

Cited Authors

  • Sommer, DB; Stacy, MA

Published Date

  • December 2008

Published In

Volume / Issue

  • 8 / 12

Start / End Page

  • 1829 - 1839

PubMed ID

  • 19086879

Pubmed Central ID

  • 19086879

Electronic International Standard Serial Number (EISSN)

  • 1744-8360

International Standard Serial Number (ISSN)

  • 1473-7175

Digital Object Identifier (DOI)

  • 10.1586/14737175.8.12.1829


  • eng